Moreover, PARP1 was found to be a prognostic biomarker for a poor clinical outcome in breast cancer patients (Mazzotta et al., 2016), therefore PARP1 inhibitors were extensively studied as a promising class of anticancer agents (Liang and Tan, 2010). This evidence concerns the gene PARP1 and breast carcinoma.